Vaccinogen Announces Addition of David Hatt to its Board of Directors
Mar 1, 2009
Frederick, MD, USA – March 1, 2009 – Vaccinogen, Inc. announces that David Hatt, a Vaccinogen shareholder, has agreed to join Vaccinogen’s Board of Directors. As Chief Country Officer – Deutsche Bank Group, Japan, Mr. Hatt brings vast experience in the areas of capital formation strategies to Vaccinogen.
Mr. Hatt joins Michael G. Hanna, Jr., Ph.D., Founder, Chairman & CEO; John Nicolis, Vice Chairman & Partner of Optimal Asia in Australia; and Tony Caplin, Non Executive Director and Chairman of Panmure Gordon in London.
"It is a pleasure to have David join our Board," said Michael G. Hanna, Jr., Ph.D. "As we continue to build Vaccinogen into a global solution provider for cancer, it is critical that we have people of David’s caliber help us chart our strategy."
About David Hatt
Mr. Hatt’s responsibilities at Deutsche Bank are coordinating the Group’s business activities in that region. Mr. Hatt was previously with Nikko Citigroup where he was head of capital markets and co-head of institutional equities for Japan. Other roles included co-head of investment banking at Citigroup for Australia & New Zealand, Merrill Lynch in London and Salomon Smith Barney.
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth “booster” is administered six months later. OncoVAX® reduces recurrence and deaths by over 50%.
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, antiinflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX® vaccines.
Vaccinogen’s online press kit: http://www.vaccinogeninc.com/vaccinogen/press-kit
Andrew L. Tussing